

Listing of Claims:

1. (previously presented) An ApoA-I agonist compound comprising:
- (i) a 15 to 26- residue peptide or peptide analogue according to formula (I) which forms an amphipathic α -helix in the presence of lipids and exhibits at least about 38% LCAT activation activity as compared with human ApoA-I wherein one or two helical turns are deleted from formula (I), wherein a helical turn consists of 3 to 4 consecutive residues selected from residues X_1 to X_{23} of formula (I):

$Z_1-X_1-X_2-X_3-X_4-X_5-X_6-X_7-X_8-X_9-X_{10}-X_{11}-X_{12}-X_{13}-X_{14}-X_{15}-X_{16}-X_{17}-X_{18}-X_{19}-X_{20}-X_{21}-X_{22}-X_{23}-Z_2$

or a pharmaceutically acceptable salt thereof, wherein:

- X_1 is Pro (P), Ala (A), Gly (G), Gln (Q), Asn (N), Asp (D) or D-Pro (p);
 X_2 is an aliphatic residue;
 X_3 is a Leu (L) or Phe (F);
 X_4 is Glu (E)
 X_5 is an aliphatic residue;
 X_6 is Leu (L) or Phe (F);
 X_7 is Glu (E) or Leu (L);
 X_8 is Asn (N) or Gln (Q);
 X_9 is Leu (L);
 X_{10} is Leu (L), Trp (W) or Gly (G);
 X_{11} is an acidic residue;
 X_{12} is Arg (R);
 X_{13} is Leu (L) or Gly (G);
 X_{14} is Leu (L), Phe (F) or Gly (G);
 X_{15} is Asp (D);
 X_{16} is Ala (A);
 X_{17} is Leu (L);
 X_{18} is Asn (N) or Gln (Q);
 X_{19} is a basic residue;
 X_{20} is a basic residue;
 X_{21} is Leu (L);
 X_{22} is a basic residue;

X₂₃ is absent or a basic residue;

Z₁ is H₂N- ;

Z₂ is -C (O) NRR or -C (O) OR;

each R is independently -H, (C₁-C₆) alkyl, (C₁-C₆) alkenyl, (C₁-C₆) alkynyl, (C₅-C₂₀) aryl, (C₆-C₂₆) alkaryl, 5-20 membered heteroaryl or 6-26 membered alkheteroaryl or a 1 to 7-residue peptide or peptide analogue in which one more bonds between residues 1-7 are independently a substituted amide, an isostere of an amide or an amide mimetic; and

each “-” between residues X₁ to X₂₃ and between residues of the peptide to Z₂ independently designates an amide linkage, a substituted amide linkage, an isostere of an amide or an amide mimetic; or

an N- terminally blocked form, a C-terminally blocked form, or an N- and C-terminally blocked form of formula (I).

2-55. (canceled)

56. (previously presented) The 15 to 26-residue peptide or deleted peptide analogue of Claim 1, in which one helical turn is deleted.
57. (previously presented) The 15 to 26-residue peptide or peptide analogue of Claim 1, in which three, four, six, seven or eight residues X₁ , X₂ , X₃ , X₄ , X₅ , X₆ , X₇ , X₈ , X₉ , X₁₀ , X₁₁ , X₁₂ , X₁₃ , X₁₄ , X₁₅ , X₁₆ , X₁₇ , X₁₈ , X₁₉ , X₂₀ , X₂₁ and X₂₂ are deleted.
58. (previously presented) The 15 to 26-residue peptide or peptide analogue of Claim 57, in which 3 consecutive residues are deleted.
59. (previously presented) The 15 to 26-residue peptide or peptide analogue of Claim 57, in which 4 consecutive residues are deleted.
60. (previously presented) The 15 to 26-residue peptide or peptide analogue of Claim 57, in which two non-contiguous sets of 3 consecutive residues are deleted.
61. (previously presented) The 15 to 26-residue peptide or peptide analogue of Claim 57, in which two non-contiguous sets of 4 consecutive residues are deleted.

62. (previously presented) The 15 to 26-residue peptide or peptide analogue of Claim 57, in which one set of 3 consecutive residues and one set of 4 consecutive residues are deleted.
63. (previously presented) The 15 to 26-residue peptide or peptide analogue of Claim 57, in which 6, 7 or 8 consecutive residues are deleted.
- 64-66. (canceled)
67. (previously presented) The 15 to 26-residue peptide or peptide analogue of Claim 1 in which:

the “-” between residues designates -C (O) NH- ;
Z₁ is H₂N- ; and
Z₂ is -C (O) OH or a salt thereof.
68. (previously presented) The 15 to 26-residue peptide or peptide analogue of Claim 1, in which the mean hydrophobic moment, $\langle \mu_H \rangle$, is 0.45 to 0.65.
69. (previously presented) The 15 to 26-residue peptide or peptide analogue of Claim 68, in which the mean hydrophobic moment, $\langle \mu_H \rangle$, is 0.50 to 0.60.
70. (previously presented) The 15 to 26-residue peptide or peptide analogue of Claim 1, in which the mean hydrophobicity, $\langle H_o \rangle$, is -0.050 to -0.070.
71. (previously presented) The 15 to 26-residue peptide or peptide analogue of Claim 1, in which the mean hydrophobicity, $\langle H_o \rangle$, is -0.030 to -0.055.
72. (previously presented) The 15 to 26-residue peptide or peptide analogue of Claim 1, in which the mean hydrophobicity of the hydrophobic face, $\langle H_o^{pho} \rangle$, is 0.90 to 1.20.
73. (previously presented) The 15 to 26-residue peptide or peptide analogue of Claim 72, in which the mean hydrophobicity of the hydrophobic face, $\langle H_o^{pho} \rangle$, is 0.94 to 1.10.
74. (previously presented) The 15 to 26-residue peptide or peptide analogue of Claim 1, in which the pho angle is 160° to 220°.

75. (previously presented) The 15 to 26-residue peptide or peptide analogue of Claim 74, in which the ϕ angle is 180° to 200° .
- 76-78. (canceled)
79. (previously presented) A pharmaceutical composition comprising an ApoA-I agonist compound and a pharmaceutically acceptable carrier, excipient or diluent, wherein the ApoA-I agonist compound is a 15 to 26-residue peptide or peptide analogue according to Claim 1 or 57.
- 80-81. (canceled)
82. (previously presented) The pharmaceutical composition of Claim 79 which is a lyophilized powder.
83. (previously presented) The pharmaceutical composition of Claim 79 which is a solution.
84. (previously presented) The N-terminally blocked form of the 15 to 26-residue peptide or peptide analogue of Claim 1.
85. (previously presented) The 15 to 26-residue peptide or peptide analogue of Claim 84 in which the N-terminally blocking group is selected from the group consisting of acetyl, formyl and dansyl.
86. (previously presented) The C-terminally blocked form of the 15 to 26-residue peptide or peptide analogue of Claim 1.
87. (previously presented) The 15 to 26-residue peptide or peptide analogue of Claim 86 in which the C-terminally blocking group is methyl.
88. (previously presented) The N-terminally and C-terminally blocked form of the 15 to 26-residue peptide or peptide analogue of Claim 1.